2021年2月16日
Acting on transformational roll-up and $250 million crossover financing of cutting-edge UK and European biotech companies
We have advised a series of eight biotech companies on their concurrent sale into Centessa Pharmaceuticals, a newly established holding company for a group of 10 life sciences companies in Europe and North America.
Centessa Pharmaceuticals is involved in the development of innovative new treatments. We advised ApcinteX, Capella Biosciences, Inexia, LockBody Therapeutics, Morphogen-IX, Orexia, Pega-One and Z Factor on their participation in the deal.
This complex deal was led by Ross McNaughton and Ed Chapman, with IP support led by life sciences specialist Colin McCall. The transaction involved advice from across the firm’s corporate, patent, tax and incentives groups. The deal underlines our strong position in the Cambridge and wider UK market, working with companies and investors in the biotech space.
We were delighted to assist on the strategic combination and financing of these leading-edge life sciences companies. This transaction has brought together some exciting life sciences companies with a top tier international investor base. We wish the companies well in the next phases of their development under the Centessa umbrella.
Ross McNaughton | Partner
This transaction represents a sizable corporate transaction for our Life Sciences & Healthcare team, which continues to operate at the top of the market. The team works with many of the industry's cutting-edge pharmaceutical, biotechnology, and medical device companies, from leading multinationals to earlier stage enterprises ready to up-scale their business. We guide ambitious global clients within these dynamic and innovative industries through the maze of connected legal, commercial, and regulatory challenges.
